Despite encouraging clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant opposition from pharmacy benefit managers. Such companies are frequently creating obstacles to coverage, like steep expense requirements and approval processes that limit patient availability. Indust